

## **Product** Data Sheet

# **Atuliflapon**

Cat. No.: HY-122908 CAS No.: 2041075-86-7 Molecular Formula:  $C_{24}H_{26}N_6O_3$ Molecular Weight: 446.5

Target: FLAP

Pathway:

Storage: 4°C

In solvent -80°C 6 months

Immunology/Inflammation Powder -20°C 3 years 2 years

> -20°C 1 month

#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 125 mg/mL (279.96 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.2396 mL	11.1982 mL	22.3964 mL
	5 mM	0.4479 mL	2.2396 mL	4.4793 mL
	10 mM	0.2240 mL	1.1198 mL	2.2396 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.66 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- $\beta$ -CD in saline) Solubility: ≥ 2.08 mg/mL (4.66 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.66 mM); Clear solution

### **BIOLOGICAL ACTIVITY**

Description	Atuliflapon (AZD5718) is an orally active inhibitor of FLAP (5\(\text{MLipoxygenase}\) activating protein), with an IC <sub>50</sub> of 2 nM. Atuliflapon is used in the study for coronary artery disease <sup>[1]</sup> .
IC <sub>50</sub> & Target	IC50: 2 nM (FLAP) <sup>[1]</sup> .
In Vitro	Atuliflapon demonstrates a dose dependent and greater than 90% suppression of leukotriene production over 24 h $^{[1]}$ . Atuliflapon exhibits an IC $_{50}$ of 39 nM for LTB $_{4}$ $^{[1]}$ .

	MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Atuliflapon exhibits $t1/2$ of 0.45 h and 2.1 h in rat and dog by iv injection, respectively <sup>[1]</sup> . Atuliflapon shows no inhibition of 5-LO pathway activity in rodent blood <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

[1]. Daniel Pettersen, et al. Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease. J Med Chem. 2019 May 9;62(9):4312-4324.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com